BOSTON — Vertex Pharmaceuticals reshaped the way doctors treat cystic fibrosis, turning what was once a childhood death sentence into a manageable condition — and making the Boston biotech a multibillion-dollar company in the process.
Its next goal? Reproducing that success.
The company’s executives on Tuesday laid out an ambitious vision for the company’s future, one they dubbed “Vertex 3.0.” It’s one in which Vertex is taking aim at everything from diabetes to sickle cell disease to pain. Many of these programs have reached clinical trials, with others buttressed by laboratory studies supporting the safety and effectiveness of experimental therapies.
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect